corporate ehs strategic perspective michael rottas associate director, environmental health &...

24
Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Upload: reynard-west

Post on 26-Dec-2015

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Corporate EHS Strategic Perspective

Michael Rottas

Associate Director, Environmental Health & Safety

Pfizer Global R&D – Groton/New London Laboratories

Page 2: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

• Pfizer is the largest pharmaceutical company in the world.– Human health– Consumer health care– Animal health

• ~120,000 employees worldwide• Operations in 150 countries• Largest privately funded research organization

in the world.– Now ~$8 billion/year – Groton Labs ~$1.5 billion/year

Page 3: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

• Global Environmental Management Initiative (GEMI) member

• UN Global Compact member• EPA Climate Leaders participant• Public Environmental Goals:

– Reduce CO2 emissions by 35% by 2007 (2000 as baseline)

– 35% of global electricity needs by 2010 from clean sources

– Phase out of Class I ODCs by 12/31/2005

Page 4: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Where we were…

• EHS professionals, in Corporate setting, were necessary overhead due to compliance requirements

• Outsiders from manufacturing and operating units

• Us vs. them• Niche role• Reactive • After the fact• End-of-line control

Page 5: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Where we are…

• EHS professionals are a respected participant in the business process

• We are at the table• Resource for business risk minimization and

continuity planning (post Y2K, post 9/11/2001)

• Skills transferable, financially savvy• Proactive and preventative• Third party EMS registrations

Page 6: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Where we are going…

• Holistic approach to sustainable practices• Integrated EHS management systems• No longer separate, but integrated into core

business functions• Technical professionals with sophisticated

business skills (MBAs routine)• Everyone is involved, cultural approach

Page 7: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Industrial Evolution

• Sustainability becoming more commonplace within the core business of leading businesses– Hybrid cars becoming mainstream– Petrochemical companies working on alternative

fuels– Carpet companies making recyclable carpets– Pharmaceutical companies doing green chemistry

• Investment firms recognize value in sustainable practices

Page 8: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

What is green chemistry?

“…the utilization of a set of principles that reduces or eliminates the use or generation of hazardous substances in the design, manufacture and application of chemical products.”

*Source: Paul T. Anastas and John C. Warner, Green Chemistry: Theory and Practice (New York, NY: Oxford University Press Inc., 1998).ISBN 0 19 850698 8

Page 9: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

1. It is better to prevent waste than to treat or clean up waste after it has formed.

2. Synthetic methods should be designed to maximize the incorporation of all materials used in the process into the final product.

3. Wherever practicable, synthetic methodologies should be designed to use and generate substances that possess little or no toxicity to human health and the environment.

4. Chemical products should be designed to preserve efficacy of function while reducing toxicity.

5. The use of auxiliary substances (e.g. solvents, separation agents, etc.) should be made unnecessary wherever possible and innocuous when used.

6. Energy requirements should be recognized for their environmental and economic impacts and should be minimized. Synthetic methods should be conducted at ambient temperature and pressure.

12 Principles of Green Chemistry*

Page 10: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

12 Principles of Green Chemistry*7. A raw material or feedstock should be renewable rather than depleting

wherever technically and economically practicable.8. Unnecessary derivatization (blocking group, protection/deprotection,

temporary modification of physical/chemical processes) should be avoided wherever possible.

9. Catalytic reagents (as selective as possible) are superior to stoichiometric reagents.

10. Chemical products should be designed so that at the end of their function they do not persist in the environment and break down into innocuous degradation products.

11. Analytical methodologies need to be further developed to allow for real-time, in-process monitoring and control prior to the formation of hazardous substances.

12. Substances and the form of a substance used in a chemical process should be chosen so as to minimize the potential for chemical accidents, including releases, explosions and fires.

Page 11: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Global R&D

Raw Materials

Energy

Natural Resources

NDAIntellectual Property

Clinical Supply

PGM

Raw Materials

Energy

Natural Resources

Product

Waste

Solid/Hazardous Wastes

Air Emissions

Wastewater

Page 12: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Global R&D

Raw Materials

Energy

Natural Resources

NDAIntellectual Property

Clinical Supply

PGM

Raw Materials

Energy

Natural Resources

Product

Waste

Solid/Hazardous Wastes

Air Emissions

Wastewater

Waste MinimizationPollution Prevention

Control at the source,treat on or off-site,recycle where possible.Reduce, reuse, recycle.

Page 13: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Global R&D

Raw Materials

Energy

Natural Resources

NDAIntellectual Property

Clinical Supply

PGM

Raw Materials

Energy

Natural Resources

Product

Waste

Solid/Hazardous Wastes

Air Emissions

Wastewater

Green Chemistry

Waste MinimizationPollution Prevention

Page 14: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Sertraline (Zoloft)

• Solvent use reduced from 60,000 to 6,000 gallons per ton of sertraline

• Eliminated the use of 440 metric tons of titanium dioxide per year

• Eliminating the use 150 metric tons of 35% hydrochloric acid per year

• Eliminating the use of 100 metric tons of 50% sodium hydroxide per year

• Increasing the efficiency of raw material, water and energy use

• And, doubled the product yield.

Page 15: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

232 L/kgDiscovery Route

98 L/kg1st Commercial

81 L/kg2nd Commercial

26 L/kg3rd Commercial

8 L/kg Chiral Tetralone

Methanol

Ethyl acetate

Ethanol

THF

Hexane

Toluene

Methylene chloride

Sertraline Process – Solvent Waste/Kg

Page 16: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

EPA’s Presidential

Green Chemistry Challenge Award

- 2002

Page 17: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

1816 L/kg MedicinalChemistry

1990

139 L/kgOptimized

Med. Chemistry1994

31 L/kgCommercial Route

(1997)

10 L/kgCommercial Route following solvent

recovery

Pyridine

Toluene

t-Butanol

2-Butanone

Ethyl Acetate

Ether

Methanol

Ethanol

Acetone

Methylene Chloride

How the amount of waste produced in the manufacture of sildenafil (L of waste/kg of product) has decreased over the past 13 years.

Page 18: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Who “does” green chemistry?

• Chemists

• EHS folks may assist with making the business case and providing inspiration/recognition, but ultimately it’s the chemists who do this.

• Example of integration

Page 19: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Why Green Chemistry?

• Meets the challenge of the triple bottom line:– Economic– Social– Environmental

Page 20: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Green Chemistry & TBL

Economic Aspect• Lower cost of raw materials• Lower costs for environmental permitting and

regulatory requirements• Lower costs on engineering controls for employee

safety• Risk of loss due to accidents, on a macro

perspective, decreases• Lower costs for environmental emissions control and

treatment• Lower costs associated with inventory control• Competitive advantage

Page 21: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Social Aspect• Fence line issues (odors, unplanned releases)• Resource sustainability for future generations• Public outreach/education programs• Pfizer reputation – they expect us to do this

Green Chemistry & TBL

Page 22: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

Environmental Aspect• More efficient use of non-renewable natural

resources• Less impact on the environment due to

permitted wastewater discharges, air emissions, and hazardous waste treatment

• Less risk of incidents and unplanned releases• Smaller environmental footprint

Green Chemistry & TBL

Page 23: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories

The Nobel Prize in Chemistry 2005The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry for 2005 jointly to

Yves ChauvinInstitut Français du Pétrole, Rueil-Malmaison, France,Robert H. GrubbsCalifornia Institute of Technology (Caltech), Pasadena, CA, USA andRichard R. SchrockMassachusetts Institute of Technology (MIT), Cambridge, MA, USA

“for the development of the metathesis method in organic synthesis.”

Page 24: Corporate EHS Strategic Perspective Michael Rottas Associate Director, Environmental Health & Safety Pfizer Global R&D – Groton/New London Laboratories